Skip to main content

Advertisement

SpringerLink
Log in

Role of Platinum in Early-Stage Triple-Negative Breast Cancer

  • Breast Cancer (ML Telli, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Triple-negative breast cancer (TNBC) is both a clinically and genomically heterogeneous disease, with distinct molecular subtypes; however, most epidemiologic and clinical studies to date have defined it under a “one disease” umbrella. This is an important point, since one therapeutic approach for all TNBCs is unlikely to be successful given the underlying biological diversity. In this review, we explore the role of platinums in the treatment of TNBC, as well as the potential for biomarkers to predict patient response to these agents. The results of neoadjuvant TNBC trials, with addition of platinum to anthracycline/taxane-based chemotherapies, have been very encouraging given increases in pathologic complete response (pCR) rates. However, we do not have any evidence yet that these agents would lead to improvement in disease-free and overall survival. Moreover, addition of platinums increases toxicity and can compromise current standard chemotherapy doses, which further impedes their use in all TNBC patients. Therefore, the addition of platinums to standard chemotherapy should be used with caution and in discussion with patients after a careful assessment of risks and benefits. Clinical trials addressing the role of platinums in TNBC further remain of significant value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. https://doi.org/10.1056/NEJMra1001389.

    Article  CAS  PubMed  Google Scholar 

  2. Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. https://doi.org/10.1172/JCI45014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(19):5533–40. https://doi.org/10.1158/1078-0432.CCR-13-0799.

    Article  CAS  Google Scholar 

  5. Weisman PS, Ng CK, Brogi E, Eisenberg RE, Won HH, Piscuoglio S, et al. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2016;29(5):476–88. https://doi.org/10.1038/modpathol.2016.39.

    Article  CAS  Google Scholar 

  6. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.

    Article  Google Scholar 

  7. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–8. https://doi.org/10.1245/s10434-013-3205-1.

    Article  PubMed  Google Scholar 

  8. Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, et al. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev. 2013;39(5):541–50. https://doi.org/10.1016/j.ctrv.2012.12.001.

    Article  CAS  PubMed  Google Scholar 

  9. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33(11):2007–17. https://doi.org/10.1093/carcin/bgs232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Johnstone TC, Park GY, Lippard SJ. Understanding and improving platinum anticancer drugs—phenanthriplatin. Anticancer Res. 2014;34(1):471–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81. https://doi.org/10.1200/jco.2007.14.4147.

    Article  PubMed  Google Scholar 

  12. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804. https://doi.org/10.1200/jco.2011.38.8595.

    Article  Google Scholar 

  13. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology). J Clin Oncol. 2017; https://doi.org/10.1200/JCO.2016.71.4147.

  14. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145–53. https://doi.org/10.1200/JCO.2009.22.4725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. • von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. The Lancet Oncology. 2014;15(7):747–56. https://doi.org/10.1016/S1470-2045(14)70160-3. One of the randomized phase II TNBC trials with incorporation of platinum showing increased pCR rate.

    Article  Google Scholar 

  16. de Minckwitz G LS, Schneeweiss A, Salat CT, Rezai M, Zahm D-M, Klare P. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Presented at 2015 San Antonio Breast Cancer Symposium San Antonio, Texas; December 8–12, 2015.

  17. • Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21. https://doi.org/10.1200/JCO.2014.57.0572. One of the randomized phase II TNBC trials with incorporation of platinum showing increased pCR rate.

    Article  CAS  PubMed  Google Scholar 

  18. Sikov WM BD, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Somlo G, Port ER, Qamar R, Sturtz K, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/− carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Presented at 2015 San Antonio Breast Cancer Symposium San Antonio, Texas; December 8–12, 2015.

  19. • Rugo HS, Olopade OI, DeMichele A, Yau C, van’t Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34. https://doi.org/10.1056/NEJMoa1513749. Results of veliparib-carboplatin treatment arm from I-SPY2 trial.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. A randomized, placebo-controlled, double-blind, phase 3 study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage triple negative breast cancer (TNBC). NCT02032277.

  21. NRG-BR003: a randomized phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer. NCT02488967.

  22. A randomized phase III post-operative trial of platinum based chemotherapy vs. capecitabine in patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy. NCT02445391.

  23. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94(5):1517–36.

    CAS  PubMed  Google Scholar 

  24. Sparano JA. Defining a role and predicting benefit from platinum-based therapy in breast cancer: an evolving story. J Clin Oncol. 2015;33(1):1–3. https://doi.org/10.1200/JCO.2014.57.7890.

    Article  CAS  PubMed  Google Scholar 

  25. • Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895–901. https://doi.org/10.1200/JCO.2014.57.0085. Single-arm neoadjuvant trial incorporating platinum into a non-anthracycline-based chemotherapy in TNBC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375–9. https://doi.org/10.1200/JCO.2008.20.7019.

    Article  CAS  PubMed  Google Scholar 

  27. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–63. https://doi.org/10.1007/s10549-008-0128-9.

    Article  CAS  PubMed  Google Scholar 

  28. Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, et al. Genomic complexity profiling reveals that HORMAD1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers. Cancer discovery. 2015;5(5):488–505. https://doi.org/10.1158/2159-8290.CD-14-1092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(15):3764–73. https://doi.org/10.1158/1078-0432.CCR-15-2477.

    Article  CAS  Google Scholar 

  30. Tung NM, Winer EP. Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. J Clin Oncol. 2015;33(9):969–71. https://doi.org/10.1200/JCO.2014.59.6031.

    Article  CAS  PubMed  Google Scholar 

  31. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91. https://doi.org/10.1200/JCO.2014.58.1967.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Case Comprehensive Cancer Center, Case Western Reserve University, Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106, USA

    Alyssa La Belle BS, William P. Schiemann PhD & Shaveta Vinayak MD, MS

  2. Department of Internal Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA

    Jude Khatib MD

  3. Case Comprehensive Cancer Center, Case Western Reserve University, Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106, USA

    William P. Schiemann PhD

  4. Division of Hematology and Oncology, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, LKS 5079, Cleveland, OH, 44106, USA

    Shaveta Vinayak MD, MS

Authors
  1. Alyssa La Belle BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jude Khatib MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William P. Schiemann PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shaveta Vinayak MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to William P. Schiemann PhD or Shaveta Vinayak MD, MS.

Ethics declarations

Conflict of Interest

Alyssa La Belle, Jude Khatib, William P. Schiemann, and Shaveta Vinayak declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

A.L.B. and J.K. were equal contributors to this work.

This article is part of the Topical Collection on Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

La Belle, A., Khatib, J., Schiemann, W.P. et al. Role of Platinum in Early-Stage Triple-Negative Breast Cancer. Curr. Treat. Options in Oncol. 18, 68 (2017). https://doi.org/10.1007/s11864-017-0506-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0506-9

Keywords

Search

Navigation